American Century Companies Inc. Has $40.54 Million Holdings in Repligen Co. (NASDAQ:RGEN)

American Century Companies Inc. decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 2.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 281,658 shares of the biotechnology company’s stock after selling 5,743 shares during the quarter. American Century Companies Inc.’s holdings in Repligen were worth $40,542,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of Repligen during the 3rd quarter worth approximately $166,000. Charles Schwab Investment Management Inc. increased its holdings in Repligen by 1.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock worth $54,078,000 after buying an additional 5,478 shares during the last quarter. Cerity Partners LLC raised its position in Repligen by 90.0% during the third quarter. Cerity Partners LLC now owns 5,541 shares of the biotechnology company’s stock worth $825,000 after acquiring an additional 2,625 shares in the last quarter. Bank of Montreal Can lifted its stake in Repligen by 34.9% in the third quarter. Bank of Montreal Can now owns 49,568 shares of the biotechnology company’s stock valued at $7,233,000 after acquiring an additional 12,816 shares during the last quarter. Finally, Townsquare Capital LLC grew its position in shares of Repligen by 5.0% in the 3rd quarter. Townsquare Capital LLC now owns 14,106 shares of the biotechnology company’s stock valued at $2,099,000 after acquiring an additional 670 shares during the period. Institutional investors own 97.64% of the company’s stock.

Insider Activity at Repligen

In other news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several recent analyst reports. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $178.64.

Repligen Stock Down 1.7 %

Shares of RGEN opened at $137.12 on Friday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.70 billion, a PE ratio of -268.86, a P/E/G ratio of 4.54 and a beta of 0.95. The firm’s 50 day moving average is $154.75 and its 200-day moving average is $148.22. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $187.25.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Equities research analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.